Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

2 GLP-1 receptor agonists mimic the body’s production of GLP-1 and are approved to treat patients with obesity and type 2 diabetes. 1 GLP-1 receptor agonists activate the GLP-1 receptors located ...

In older adults with diabetes, GLP-1 receptor agonists ... molecular structure of GLP-1 agonist agent (semaglutide [Ozempic], ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used ... For example, research has shown that treatment with Ozempic, Trulicity, Rybelsus, or Victoza is linked to ...

For people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting, researchers said here. In a systematic review and meta-analysis of three ...

There is also a similar medication called tirzepatide (Mounjaro/Zepbound), which is a dual GLP-1/GIP receptor agonist. This means it works on GLP-1, as well as another receptor called glucose ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments ...

Seven different GLP-1 receptor agonists were investigated among the trials, including semaglutide (also known as Ozempic or Wegovy), dulaglutide (Trulicity) and liraglutide (Victoza). The results ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, significantly reduce post-cessation weight gain in individuals quitting smoking, with users losing weight compared to controls.

GLP-1 receptor agonists promote the feeling of fullness before eating via neurons in the dorsomedial hypothalamus, according to a new study. The findings offer new insights into the neural ...

Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for depression risk between new ...